BOULDER, Colo., Nov. 29, 2016 /PRNewswire/ -- Several leading
Alzheimer's disease experts will participate in a webinar hosted by
Accera, Inc. at 11 a.m. EST on
December 6 in advance of the 9th
Annual International Conference on Clinical Trials for Alzheimer's
Disease (CTAD). The program will include discussions on the role of
metabolism in Alzheimer's disease and therapeutic targets that
address deficient glucose metabolism observed in Alzheimer's
disease patients.
"Following the recent failure of another therapy targeting the
amyloid hypothesis, now more than ever we need to focus on
alternative mechanisms to address Alzheimer's disease," said
Michael Gold, M.D., Accera's senior
medical advisor and the moderator of the webinar. "As the
Alzheimer's community prepares to gather for CTAD, we want to
provide perspectives from researchers leading the way to address
the fundamental metabolic defect in Alzheimer's patients."
Dr. Gold will moderate a discussion following presentations
by:
- Russell Swerdlow, M.D., Gene and Marge Sweeney Professor of
Neurology, University of Kansas
Dr. Swerdlow will present
information about the history of the metabolic hypothesis and the
role of mitochondrial defects in Alzheimer's disease. He is the
Director of the University of Kansas
Alzheimer's Disease Center and the KUMC Neurodegenerative Disorders
Program. Dr. Swerdlow is a Professor in the Departments of
Neurology, Molecular and Integrative Physiology, and Biochemistry
and Molecular Biology at the University of
Kansas School of Medicine. After receiving his undergraduate
and doctor of medicine degrees from New York
University, he trained as a neurologist and cognitive
disorders subspecialist at the University of
Virginia. Dr. Swerdlow sees patients at the University of Kansas Memory Disorders Clinic and is
a laboratory-based neuroscientist who is internationally known for
his work on mitochondrial dysfunction in neurodegenerative
diseases.
- Eugenia Trushina, Ph.D., Associate Professor in the Departments
of Neurology and Pharmacology, Mayo Clinic
Dr. Trushina will present
information on emerging mitochondria-targeted therapeutics. Her
laboratory is focused on mitochondrial dysfunction caused by
environmental toxins, chemotherapy drugs and genetic factors in
multiple neurodegenerative disorders, including Huntington's
disease and Alzheimer's disease, aging, and chemotherapy-induced
peripheral neuropathy. Her research interests involve
identification of the molecular mechanisms involved in the
inhibition of mitochondrial dynamics and function in neurons. Dr.
Trushina's current projects include the development of a panel of
the biomarkers associated with mitochondrial dysfunction involved
in neurodegeneration and testing novel mitochondria-targeted
therapeutic approaches that could potentially reverse
neurodegeneration and aging. Dr. Trushina has a Ph.D. from Saratov
State University in Russia and
conducted postdoctoral studies at the Mayo Clinic College of
Medicine. Dr. Trushina's research has been funded by the Mayo
Clinic Alzheimer's Disease Research Center, the American Health
Assistance Foundation, the Alzheimer Drug Discovery Foundation and
the National Institutes of Health.
Accera's lead product candidate, AC-1204, addresses the issue of
deficient glucose metabolism in Alzheimer's disease by inducing a
mild form of ketosis by generating ketones for use in neurons.
These ketones have the potential to restore the supply of energy,
improving neuronal metabolism and in turn cognition and function in
patients with mild to moderate Alzheimer's disease. AC-1204 is
currently being evaluated in a double-blind, placebo-controlled
Phase 3 study called NOURISH AD. Results from this study are
expected in the coming months.
Webinar Information
Participants can register in advance and access the webinar by
clicking the following link:
https://www.webcaster4.com/Webcast/Page/1588/18619. Participants
are encouraged to log on within 15 minutes prior to the beginning
of the webinar. Following the event, a replay will be available at
the same link and on the Accera website.
About Accera
Accera, Inc. is a clinical-stage biotechnology company based in
Boulder, Colo., that is developing
therapies for central nervous system disorders. The company's
proprietary scientific platform addresses unmet medical needs in
brain health, including Alzheimer's disease. Accera is focused on
the clinical development of drugs with innovative mechanisms of
actions. The company's management team includes globally recognized
specialists in central nervous system diseases and drug
development, who together leverage the latest scientific knowledge
and understanding of neurological disorders. Accera's lead product
candidate is AC-1204, a ketosis-inducing compound in a Phase 3
clinical study in patients with mild to moderate Alzheimer's
disease. For more information, visit www.accerapharma.com.
Follow Accera on Twitter at twitter.com/accerainc.
Accera Media Contacts:
Russo Partners LLC
Todd Davenport, Ph.D.
(212)
845-4235
todd.davenport@russopartnersllc.com
Rich
Allan
(646) 942-5588
rich.allan@russopartnersllc.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/beyond-the-failed-beta-amyloid-hypothesis----alzheimers-experts-to-discuss-need-for-new-medicines-with-alternative-mechanisms-of-action-in-pre-ctad-conference-webinar-tomorrow-300373034.html
SOURCE Accera, Inc.